Wednesday, June 04, 2014 10:59:35 PM
The GRAS program is an FDA-approved process that enables companies to conduct independent GRAS determinations through consultations with qualified experts to determine that an ingredient satisfies the FDA's safety criteria. Accordingly, GLG engaged GRAS Associates, LLC, who convened an independent panel of expert scientists to spearhead the safety assessment and compile a dossier describing the months-long study and its results. GLG subsequently submitted that dossier to the FDA for review, resulting in the FDA's letter of no objection.
To date, GLG has received five GRAS letters of no objection covering an array of high-purity stevia products, with a sixth GRAS determination pending FDA review (for high-purity rebaudioside M) and two other GRAS projects currently underway (for high-purity rebaudioside C and D). Additionally, GLG recently announced its submission of a GRAS notification to the FDA for its Luo Han Guo (Monk Fruit) extract products. GLG currently has the largest number of stevia products certified under the GRAS process.
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM